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Deciphering the molecular basis 
of mycobacteria and lipoglycan 
recognition by the C-type lectin 
Dectin-2
Alexiane Decout1,2,11, Sandro Silva-Gomes1,12, Daniel Drocourt2, Emilyne Blattes1,13, 
Michel Rivière1, Jacques Prandi1, Gérald Larrouy-Maumus1,14, Anne-Marie Caminade3, 
Beston Hamasur4,5, Gunilla Källenius6, Devinder Kaur7,15, Karen M. Dobos  7, Megan Lucas7, 
Iain C. Sutcliffe8, Gurdyal S. Besra  9, Ben J. Appelmelk10, Martine Gilleron1, Mary Jackson  7, 
Alain Vercellone1, Gérard Tiraby2 & Jérôme Nigou1
Dectin-2 is a C-type lectin involved in the recognition of several pathogens such as Aspergillus 
fumigatus, Candida albicans, Schistosoma mansonii, and Mycobacterium tuberculosis that triggers 
Th17 immune responses. Identifying pathogen ligands and understanding the molecular basis 
of their recognition is one of the current challenges. Purified M. tuberculosis mannose-capped 
lipoarabinomannan (ManLAM) was shown to induce signaling via Dectin-2, an activity that requires 
the (α1 → 2)-linked mannosides forming the caps. Here, using isogenic M. tuberculosis mutant strains, 
we demonstrate that ManLAM is a bona fide and actually the sole ligand mediating bacilli recognition 
by Dectin-2, although M. tuberculosis produces a variety of cell envelope mannoconjugates, such 
as phosphatidyl-myo-inositol hexamannosides, lipomannan or manno(lipo)proteins, that bear 
(α1 → 2)-linked mannosides. In addition, we found that Dectin-2 can recognize lipoglycans from 
other bacterial species, such as Saccharotrix aerocolonigenes or the human opportunistic pathogen 
Tsukamurella paurometabola, suggesting that lipoglycans are prototypical Dectin-2 ligands. Finally, 
from a structure/function relationship perspective, we show, using lipoglycan variants and synthetic 
mannodendrimers, that dimannoside caps and multivalent interaction are required for ligand binding 
to and signaling via Dectin-2. Better understanding of the molecular basis of ligand recognition by 
Dectin-2 will pave the way for the rational design of potent adjuvants targeting this receptor.
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Innate immune recognition is based on the detection of microbial molecular structures by host pattern recogni-
tion receptors (PRRs)1. PRRs belong to several families, among which C-type lectins are specialized in the bind-
ing of sugar moieties, via carbohydrate recognition domains (CRD) that contain one or more calcium-dependent 
carbohydrate-binding sites2. Dectin-2 (Dendritic-Associated C-type lectin-2) is a C-type lectin that was initially 
identified on murine dendritic cells3, but was subsequently shown to be expressed on several cell types, including 
macrophages4,5. It is constituted of one CRD, a transmembrane domain and a short intracellular domain devoid of 
signaling motif3. Association of Dectin-2 with a FcRγ chain triggers the recruitment and phosphorylation of the 
tyrosine kinase Syk4, formation of the Card9/Malt1/Bcl10 complex6 and translocation of NF-κB to the nucleus, 
leading to the production of cytokines and chemokines, such as TNF-α7. Syk also activates the MAPK pathway 
through the phospholipase Cγ2 and drives the production of Th17 polarizing molecules8,9.
Dectin-2 is involved in the recognition of several pathogens, such as Aspergillus fumigatus, Candida albicans 
and Schistosoma mansonii, driving the production of pro-inflammatory cytokines and inducing protective immu-
nity7,10,11. Indeed, the CRD of Dectin-2 exhibits specificity toward high mannose glycoconjugates containing 
Manα1-2Man motifs12, mainly found in fungi. The recognition of the yeast Malassezia furfur by Dectin-2 was 
shown to be mediated through an O-linked mannobiose-rich mannoprotein13. More recently, glycan array exper-
iments indicated that the presence of Manα1-2Man motifs increased the binding to Dectin-214 and, accordingly, 
the crystal structure of human Dectin-2 CRD complexed with Man9GlcNAc2 oligosaccharide revealed a canoni-
cal C-type primary monosaccharide binding site centered on a Ca2+ ion as well as a secondary binding site for a 
second mannose residue15.
In addition to fungi and yeasts, Dectin-2 has been shown to play a key role in the detection of mycobacteria 
and induction of a protective immune response in mice16. Indeed, Dectin-2 knockout mice infected by the oppor-
tunistic pathogen Mycobacterium avium show a higher bacterial load than the wild-type mice. The lipoglycan 
mannose-capped lipoarabinomannan (ManLAM) produced by the slow-growing mycobacterial species, such as 
the human pathogen Mycobacterium tuberculosis, the vaccine strain Mycobacterium bovis BCG, or M. avium, but 
not by the non-pathogenic fast-growing species, such as Mycobacterium smegmatis17,18, was identified as a ligand 
of Dectin-2 when used as a purified molecule16. Recognition of purified ManLAM by Dectin-2 required the man-
nose caps16, which are mono-, (α1 → 2)-di- or (α1 → 2)-tri-mannosyl units present on the non-reducing ends of 
its arabinan domain17. However, the mycobacterial cell envelope contains a variety of complex glycoconjugates 
that bear similar structures, such as the phosphatidyl-myo-inositol hexamannosides (PIM6), lipomannan (LM) 
and manno(lipo)proteins (M(L)P) (Fig. 1), ubiquitously found in the envelope of mycobacteria18–21. Altogether, 
several questions remain unanswered. Is ManLAM a bona fide Dectin-2 ligand in the context of M. tuberculosis 
bacilli recognition? Are there other mycobacterial ligands of Dectin-2? Are bacterial lipoglycans prototypical 
ligands of this receptor? What is the precise molecular basis of ligand recognition?
Here, using on the one hand a set of M. tuberculosis isogenic mutant strains as well as purified and synthetic 
mannoconjugates, and on the other hand a combination of biochemical and cellular assays, we investigated: (i) 
the contribution of ManLAM and other mannoconjugates in M. tuberculosis recognition by Dectin-2, and (ii) the 
structure/function relationships and the molecular basis of ligand recognition by the receptor.
Results
ManLAM is the sole mycobacterial ligand triggering signaling via and mediating M. tubercu-
losis recognition by Dectin-2. In order to first evaluate whether LM, PIM6 or M(L)P might constitute 
additional mycobacterial ligands of Dectin-2, we investigated the capacity of these compounds, purified from 
different strains, to (i) bind a soluble form of human Dectin-2 receptor (Dectin-2-Fc), (ii) induce NF-κB activa-
tion in HEK cells expressing murine Dectin-2 (HEK-Dectin-2) and a NF-κB-inducible reporter system (secreted 
alkaline phosphatase), and (iii) induce Dectin-2-dependent production of cytokines by murine bone marrow-de-
rived dendritic cells (BMDCs). In agreement with published data16, ManLAM purified from M. tuberculosis effi-
ciently bound Dectin-2-Fc (Fig. 2A), and induced NF-κB activation in HEK-Dectin-2 cells (Figs 2B and S2A) as 
well as a Dectin-2-dependent TNF-α production by BMDCs, as demonstrated by antibody blocking experiments 
(Fig. 2C). In contrast, but as expected, phosphoinositol-capped (PILAM) from Mycobacterium fortuitum22 and 
AraLAM from Mycobacterium chelonae23, which are devoid of mannose caps (Fig. 1)17–19, failed to do so (Fig. 2). 
M. tuberculosis LM bound and induced signaling via Dectin-2, although to a much weaker extent than ManLAM 
from the same strain (Figs 1 and S2A), while surprisingly M. smegmatis LM was completely inactive (Fig. 2). Only 
subtle differences in the mannan core ramification and acylation degrees between the structure of M. tuberculosis 
and M. smegmatis LM have been described to date19 and are unlikely to explain the difference in activity. However, 
the LAM and LM purification procedure involves a gel permeation chromatographic step to separate both lipo-
glycans24,25, which is not highly resolving, and yields preparation with a slight cross-contamination between the 
compound fractions. Whereas a contamination of M. smegmatis LM with PILAM from the same species would 
have no impact since PILAM is not a ligand of Dectin-2, a contamination of M. tuberculosis LM by ~1% of the 
strong agonist ManLAM would explain the activity observed for the former (Fig. S2A). Biochemical analysis of 
the M. tuberculosis LM batch used indeed confirmed a slight contamination by ManLAM, as demonstrated by the 
detection of arabinose after total acid hydrolysis (Fig. S2B). Accordingly, degradation of contaminating ManLAM 
by selective mild acid hydrolysis of its arabinan domain completely abrogated M. tuberculosis LM binding to 
and signaling via Dectin-2 (Fig. 2), while it did not affect LM ability to activate TLR2 (Fig. S2C). PIM6 bound 
weakly to Dectin-2-Fc (Fig. 2A), but failed to induce signaling in HEK-Dectin-2 cells or BMDCs (Fig. 2B and C). 
We finally tested two of the most abundant M(L)P purified from M. tuberculosis: the 19 kDa MLP (LpqH) and 
45 kDa MP (Apa)20,26,27. The 19 kDa MLP, but not 45 kDa MP, bound and slightly induced signalling via Dectin-2 
(Fig. 2). However again, depletion of ManLAM by anti-LAM antibody treatment completely abrogated the 19 kDa 
MLP Dectin-2-dependant activity (Fig. 2), while 19 kDa MLP remained potent at stimulating TLR2 (Fig. S2D). 
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Altogether, although PIM6 weakly bound to Dectin-2, among all the mannoconjugates tested, ManLAM appears 
to be the sole mycobacterial ligand able to induce signaling via this receptor.
In order to evaluate the contribution of ManLAM, and other possible ligands, to M. tuberculosis recognition 
by Dectin-2, we investigated the capacity of different mutant strains to bind or induce signaling via the recep-
tor. A M. tuberculosis ΔRv1635c/CapA mutant strain, which produces a LAM devoid of mannose caps (Fig. 1) 
while other mannoconjugates remain intact28,29, completely failed, in contrast to the wild-type and comple-
mented strains, to bind Dectin-2-Fc (Fig. 3A). However, a M. tuberculosis ΔRv1159/PimE mutant strain, which is 
impaired for the production of PIM6 and accumulates PIM glycoforms devoid of (α1 → 2)-linked units30 (Figs 1 
and S3), and a M. tuberculosis ΔRv1002c/PMT mutant strain, which is deficient for protein O-mannosylation20 
(Fig. 1), bound Dectin-2-Fc as efficiently as their wild-type counterparts (Fig. 3A). Finally, the capacity of a bacte-
rial lysate to induce NF-κB activation in HEK-Dectin-2 cells, as well as a Dectin-2-dependent TNF-α production 
by BMDCs, was fully abrogated in the ΔRv1635c/CapA mutant strain (Fig. 3B and C).
Thus, ManLAM is concluded to be the sole ligand mediating M. tuberculosis recognition by Dectin-2.
Dimannoside caps are required for ManLAM, and related lipoglycans, binding to and signa-
ling via Dectin-2. The mannose caps are necessary for ManLAM recognition by Dectin-216. However, 
these motifs are heterogeneous and consist of mono-, (α1 → 2)-di- or (α1 → 2)-tri-mannosyl units17. In order 
to assess the impact of the mannose cap length, we used ManLAM purified from a M. tuberculosis ΔRv2181 
mutant strain, which harbours single mannose residues at the non-reducing arabinan termini instead of 
(α1 → 2)-linked oligomannosides31 (Fig. 1). In contrast to wild-type ManLAM, ManLAM capped with single 
mannose units failed to bind or induce signaling via Dectin-2, while, as expected32,33, it was still able to activate 
TLR2 (Fig. 4). Thus, at least dimannoside caps are required for ManLAM recognition by Dectin-2, in agree-
ment with the reported i) glycan array analyses showing selective binding of the Dectin-2 CRD to glycans 
Figure 1. Chemical structure of the natural and synthetic mannoconjugates evaluated. AraLAM, 
lipoarabinomannan devoid of caps; LM: lipomannan; ManLAM, mannose-capped lipoarabinomannan; M(L)P, 
manno(lipo)proteins; M2M, M2D, second-generation mannodendrimers capped with mono- or di-mannosides 
respectively; PILAM, phospho-myo-inositol-capped lipoarabinomannan; PIM4, phosphatidyl-myo-inositol 
tetramannosides; PIM6: phosphatidyl-myo-inositol hexamannosides; RruLAM; LAM from R. ruber; SaeLM, 
LM from S. aerocolonigenes; TotLAM, LAM from T. otitidis; TpaLAM, LAM from Ts. paurometabola. Detailed 
structures are shown in Fig. S1. (b+/−, s+/−) indicates the ability (+) or not (−) of the mannoconjugates to 
bind (b) or induce signaling (s) via Dectin-2.
www.nature.com/scientificreports/
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containing (α1 → 2)-linked dimannoside epitopes14,15, and ii) the crystal structure of the CRD in complex with a 
mammalian-type high-mannose Man9GlcNAc2 revealing two monosaccharide binding sites that allow the inter-
action of dimannosides15.
Interestingly, bacteria belonging to genera phylogenetically close to mycobacteria produce lipoglycans with 
structures related to LAM32. LAM from Tsukamurella paurometabola (TpaLAM)34 and LM from Saccharotrix 
aerocolonigenes (SaeLM)35 contain (α1 → 2)-linked dimannoside side chains, whereas LAM from Turicella otiti-
dis (TotLAM)36 or Rhodococcus ruber (RruLAM)37 show single terminal mannose units only as in mycobacterial 
LM (Fig. 1). SaeLM and TpaLAM, but not TotLAM or RruLAM, were able to bind and induce signaling via 
Dectin-2 (Fig. 5), further supporting the structure/function relationship conclusions drawn with mycobacterial 
lipoglycans. However, if (α1 → 2)-linked dimannosides are required for the recognition by the CRD, they are not 
sufficient since both PIM6 and M(L)P fail to induce signaling via Dectin-2.
Signaling via Dectin-2 relies on multivalent interaction. High avidity recognition by C-type lec-
tins relies on multivalent binding that accumulates the strength of the multiple low affinities of the interaction 
between individual CRDs and oligosaccharides38,39. We previously found that high avidity recognition of purified 
ManLAM by the C-type lectins Mannose Receptor or DC-SIGN requires a ManLAM supramolecular organi-
zation induced by the aggregation of fatty acids in aqueous solution21,40,41. Indeed, although fatty acids do not 
directly interact with the receptor, they are involved in the 3D conformational presentation of the mannose caps 
and are required for high avidity binding of ManLAM. Accordingly, deacylation of ManLAM completely abro-
gated its ability to bind and induce signaling via Dectin-2 (Fig. 6). With the aim to mimic the bioactive supra-
molecular structure of ManLAM, we recently designed and chemically synthesized a set of mannodendrimers, 
made of poly(phosphorhydrazone) dendrimers grafted with (α1 → 2)-linked mannose caps (Figs 1 and S1), that 
bind and induce signaling via DC-SIGN as efficiently as the natural M. tuberculosis molecule42. Whatever the 
dendrimer generation, mannodendrimers grafted with dimmanoside or trimannoside caps bound Dectin-2-Fc 
Figure 2. ManLAM, but not the other mycobacterial cell envelope mannoconjugates tested, induce cell 
signaling via Dectin-2. Mannoconjugates (1 µg in (A,B) 0.1 µg in (C)) were coated in 96-well plates and tested 
for their capacity to bind Dectin-2-Fc (A), and to induce NF-κB activation in HEK-Dectin-2 cells (B) and 
TNF-α production by BMDCs. (A) Dectin-2-Fc or IgG1-Fc control proteins (1 μg/ml) were pre-incubated 
or not with 20 mM EDTA or 40 mM mannose and allowed to react with the mannoconjugates for 2 h at RT. 
Bound proteins were detected using a biotin-conjugated anti-IgG Fcγ specific antibody and avidin-HRP, and 
reading O.D. at 450 nm. (B) HEK-Dectin-2 cells were stimulated for 24 h and NF-κB activation was determined 
by measuring alkaline phosphatase activity and reading O.D. at 630 nm. (C) BMDCs were stimulated for 24 h 
and TNF-α release in the supernatant was quantified by ELISA. Dectin-2 dependence was investigated by 
pre-incubating cells for 30 min at 37 °C with 5 μg/ml of anti-Dectin-2 or rIgG2a isotype control antibodies. 
Data show mean ± SEM. Mtb, M. tuberculosis; Msm, M. smegmatis; NC, non-coated; - ManLAM, ManLAM-
depleted.
www.nature.com/scientificreports/
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as efficiently as ManLAM, whereas mannodendrimer with monomannoside caps did not (Fig. 6A), confirming 
again with the use of synthetic compounds that (α1 → 2)-linked dimannosides are required for the recognition 
by the CRD. However, none of the mannodendrimers was able to activate Dectin-2 signaling in reporter cells 
(Fig. 6B) or BMDCs (Fig. 6C), indicating that the ligand 3D conformational requirements for high avidity recog-
nition by DC-SIGN and Dectin-2 differ.
Discussion
C-type lectins play a key role in the immune system with functions including cell adhesion, glycoprotein turn-
over or pathogen recognition based either on recognition of endogenous mammalian glycans or on binding to 
glycans on micro-organisms2. The spatial arrangement of CRDs in C-type lectin oligomers, although still poorly 
understood, has long been recognized as important in determining specificity for pathogen glycans, especially 
as the selectivity of the CRDs was initially thought to be low, by binding only the terminal monosaccharides of 
glycans2,43. However, recent studies have revealed that several C-type lectin CRDs comprise extended binding 
sites that can interact with disaccharide or trisaccharide units in terminal, but also possibly in internal, posi-
tions15,39,44. The geometry, organization and amino-acid composition of the extended binding site lead to a 
selectivity towards, or preclude an efficient binding of, specific classes of oligosaccharides (containing given mon-
osaccharides and linkages: position, anomeric configuration)15. However, if the mechanisms of glycans binding to 
CRDs are increasingly well understood, how it leads to initiation of C-type lectin-associated signaling pathways 
remains almost unknown2,45.
The recently published crystal structure of human Dectin-2 CRD complexed with Man9GlcNAc2 oligosac-
charide has revealed an extended binding site providing the molecular basis for binding of Manα1-2Man in 
external or internal positions of glycans15, structures that are found in several pathogens, such as fungal mannans, 
certain bacterial lipopolysaccharides, or mycobacterial mannose-capped LAM. Accordingly, we show here that 
effective binding of Dectin-2 to ManLAM or synthetic mannodendrimers requires (α1 → 2)-linked dimannoside 
caps. Interestingly, binding was increased by addition of a third (α1 → 2)-linked mannosyl unit, as observed 
for mannodendrimers (M3T vs M4D and M2D), in agreement with the crystal structure that shows space to 
model an additional α-linked mannose residue attached to the 2-OH group of the secondary site mannose res-
idue (at the non-reducing end)15. However, substitution of the 6-OH group of the mannosyl unit bearing the 
(α1 → 2)-linked mannosyl unit at the non-reducing end impairs the binding, most probably because of a steric 
hindrance, as demonstrated by the inactivity of mycobacterial LM in contrast to SaeLM. We wish here to high-
light the observation that traces amount of the highly potent Dectin-2 ligand ManLAM were sufficient to con-
fer activity to other compounds purified from M. tuberculosis cell envelope (LM, 19 kDa MLP). When working 
with ManLAM-producing bacteria, one has thus to be cautious regarding compound purity. Surprisingly, M(L)
P did not bind Dectin-2 although they bear (α1 → 2)-linked oligomannosides. In addition, PIM6, which weakly 
binds, but also mannodendrimers, which strongly bind Dectin-2-Fc, at least as efficiently as ManLAM, failed to 
Figure 3. ManLAM is the sole ligand mediating M. tuberculosis recognition by Dectin-2. The indicated M. 
tuberculosis (Mtb) strains (106 bacilli in (A) 1 µg lysate in (B and C)) were tested for their capacity to bind 
Dectin-2-Fc (A), and to induce NF-κB activation in HEK-Dectin-2 cells (B) and TNF-α production by BMDCs 
(C). Conditions are the same as in Fig. 2. Data show mean ± SEM. compl., complemented; NC, non-coated.
www.nature.com/scientificreports/
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induce signaling. This probably results from their inability to establish adequate multivalent interactions with 
Dectin-2, which are required for efficient high avidity binding to and triggering of intracellular signaling via 
the membrane-expressed receptor. Mannodendrimers were previously designed and chemically synthesized to 
mimic the bioactive supramolecular structure of ManLAM, and to bind and induce signaling via DC-SIGN42. 
Third-generation poly(phosphorhydrazone) mannodendrimers were sufficient to induce signaling via DC-SIGN 
as efficiently as ManLAM42. However, in the present study, even a fourth-generation poly(phosphorhydrazone) 
mannodendrimer was not able to trigger signaling via Dectin-2. Increasing the generation is not likely to make 
any improvement. Other dendrimer scaffolds, with a different geometry, should rather be tested to try to obtain 
an adequate mutivalency with Dectin-2. How ligand binding initiates intracellular signaling remains arguably the 
most poorly understood mechanistic aspect of C-type lectin function2. Ligand avidity is certainly a key param-
eter, but apparently not sufficient. Mannodendrimer binding to DC-SIGN was evaluated in our previous study 
using a set of bioassays, including inhibition of HEK293 cells expressing wild-type DC-SIGN protein binding to 
mannan-coated microplates42. Interestingly, we observed that the mannodendrimer IC50 values were not com-
pletely sufficient for prediction of their capacity to induce DC-SIGN signaling in human monocyte-derived den-
dritic cells (i.e. inhibition of pro-inflammatory cytokine production by LPS-stimulated cells). Here again, binding 
to Dectin-2 was not predictive of the capacity to induce signaling. Clustering of receptors by ligand binding is 
likely to be important for signaling initiation, but so far little is known about the oligomeric state of Dectin-2 or 
stoichiometry of the complexes that form with FcRγ2.
To determine the Dectin-2 ligand(s) involved in M. tuberculosis recognition, we used a set of knockout mutant 
strains. Indeed, ligands identified using purified molecules may not be accessible or relevant in the bacterial 
envelope46–48. In contrast, physiological ligands of C-type lectins might poorly bind the receptor in a solid phase 
binding assay because of a different clustering. Finally, unsuspected Dectin-2 ligand(s) might be involved in M. 
tuberculosis recognition. However, a M. tuberculosis ΔRv1635c/CapA mutant strain, which produces a LAM 
devoid of mannose caps, completely failed, in contrast to the other mutant strains tested, to bind Dectin-2, indi-
cating that ManLAM is the sole ligand mediating M. tuberculosis recognition by Dectin-2. PIM6, which binds 
Dectin-2-Fc but does not induce signaling via the receptor, is not involved in whole bacilli recognition by 
Dectin-2 in reporter cells or BMDCs. Although we cannot completely exclude that PIM6-Dectin-2 interaction 
may play a role in other cellular contexts, this means that Dectin-2 can sense slow-growing mycobacteria (which 
Figure 4. Dimannoside caps are required for ManLAM binding to and signaling via Dectin-2. ManLAM (1 µg 
in (A) from 300 to 10 ng in (B and D) 0.1 µg in (C)) purified from M. tuberculosis wild-type or ΔRv2181 mutant 
strains were tested for their capacity to bind Dectin-2-Fc (A), to induce NF-κB activation in HEK-Dectin-2 cells 
(B) and HEK-TLR2 cells (D), and to induce TNF-α production by BMDCs (C). Conditions are the same as in 
Fig. 2. Data show mean ± SEM. NC, non-coated.
www.nature.com/scientificreports/
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Figure 5. Actinobacteria lipoglycans bearing (α1 → 2)-linked dimannoside caps bind and induce signaling via 
Dectin-2. Lipoglycans (1 µg in (A) from 300 to 10 ng in (B) 0.1 µg in (C)) were tested for their capacity to bind 
Dectin-2-Fc (A), and to induce NF-κB activation in HEK-Dectin-2 cells (B) and TNF-α production by BMDCs 
(C). Conditions are the same as in Fig. 2. Data show mean ± SEM. NC, non-coated.
Figure 6. Mannodendrimers bind but do not induce signaling via Dectin-2. Mannoconjugates (1 µg in (A) 
from 300 to 10 ng in (B) 0.1 µg in (C)) were tested for their capacity to bind Dectin-2-Fc (A), and to induce 
NF-κB activation in HEK-Dectin-2 cells (B) and TNF-α production by BMDCs (C). Conditions are the same 
as in Fig. 2. Data show mean ± SEM. dManLAM, deacylated ManLAM; M2M, M2D, second-generation 
mannodendrimers capped with mono- or di-mannosides respectively; M3T, third-generation mannodendrimer 
capped with trimannosides; M4D, fourth-generation mannodendrimer capped with dimannosides; NC, non-
coated.
www.nature.com/scientificreports/
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are mostly the pathogenic ones) but not fast-growing mycobacteria, which produce LAM devoid of mannose 
caps. This property is unique so far among C-type lectin receptors, which show different specificities towards 
mycobacteria. Indeed, Mannose Receptor can recognize several purified mycobacterial mannoconjugates, such 
as ManLAM, LM, PIM and the 19 kDa MLP and 45 kDa MP, some of them (LM, PIM and glycoproteins in gen-
eral) being also produced by fast-growing mycobacteria. Accordingly, Mannose Receptor binds both slow- and 
fast-growing mycobacteria. DC-SIGN recognizes the same purified mycobacterial mannoconjugates. However, 
surprisingly, it binds species of the M. tuberculosis complex only46. The molecular basis of this selective binding 
is not yet fully understood46–48.
Beyond mycobacteria, our data also suggest that Dectin-2 might be involved in the detection of the human 
opportunistic pathogen Ts. paurometabola, with some strains of the species reported to cause lung infection, 
lethal meningitis, and necrotizing tenosynovitis49.
Knowledge of the mechanism of carbohydrate recognition by C-type CRDs is now becoming sufficient that 
glycomimetic drugs can be envisaged2. The recent discovery that some C-type lectins can induce intracellular 
signaling and elicit cell-mediated immune responses has attracted interest in these receptors and their ligands in 
the field of adjuvants and immunomodulation45,50. Indeed, there is a growing interest in the development of vac-
cine adjuvants that direct robust Th1 and Th17 responses to subunit vaccines. An analogue of the mycobacterial 
trehalose-6,6′-dimycolate ligand of Mincle, trehalose-6,6′-dibehenate (TDB), formulated with dimethyldiocta-
decylammonium was reported to promote long-lived M. tuberculosis-specific T-cell responses in humans51 and 
completed phase I clinical trial52. Addition of a newly identified Dectin-2 ligand, the glycoprotein Blastomyces 
Eng2, to a pan-fungal subunit vaccine was recently shown to prime large numbers of Ag-specific Th17 and Th1 
cells, augment activation and killing of fungi, and protect mice from lethal fungal challenge53. Moreover, Dectin-2 
activation by ManLAM was found to trigger limited inflammatory responses that could be beneficial for the 
adjuvantation of therapeutic vaccines for infectious diseases or cancer16. Therefore, better understanding the 
molecular basis of ligand recognition by Dectin-2 will pave the way for the rational design of potent adjuvants 
targeting this receptor54.
Materials and Methods
Mannoconjugates and mycobacterial strains. Lipoglycans and lipoproteins were purified as previously 
described; ManLAM Mtb, LM Mtb and PIM6 from M. tuberculosis H37Rv, AraLAM from M. chelonae, PILAM 
from M. fortuitum, LM Msm from M. smegmatis46,55–57; TpaLAM from Ts. paurometabola34; SaeLM from S. aer-
ocolonigenes35; TotLAM from T. otitidis36; RruLAM from R. ruber37; the native 19 kDa lipoprotein58 and 45 kDa 
mannoprotein59 from M. tuberculosis H37Rv; ManLAM Mtb ΔRv2181 from M. tuberculosis H37RvΔRv218131. 
Bacterial strains were grown under the following biosafety conditions: M. tuberculosis strains (level 3), M. che-
lonae, M. fortuitum and T. otitidis (level 2), other bacterial species (level 1). Mannodendrimers were chemically 
synthesized as previously reported42.
Traces of ManLAM were removed from the purified 19 kDa mannolipoprotein solution by immunoprecipi-
tation, using magnetic beads coated with an anti-LAM antibody60. Beads (500 µg; ~10 µg antibody) were washed 
twice with PBS, added to 100 µl of the mannolipoprotein solution (at 1 mg/mL) and incubated for 1 h at room 
temperature. Using a magnet, the LAM-free supernatant was removed and used for subsequent experiments. 
ManLAM present in M. tuberculosis LM preparation was degraded by mild acid hydrolysis (0.1 M HCl for 20 min 
at 110 °C) that selectively depolymerizes the arabinan domain while keeping intact the lipomannan core34.
M. tuberculosis H37RvΔRv1635c28, M. tuberculosis H37RvΔRv1002c20, M. tuberculosis H37RvΔRv1159 (see 
below), and corresponding wild-type strains were grown as surface pellicle in 7H9 medium supplemented with 
ADC. For binding experiments to Dectin-2-Fc (see below), bacteria were dissociated by gentle shaking for 30 s 
with 4-mm glass beads and numbered with a Thoma cell counting chamber. To prepare a bacterial lysate contain-
ing lipoglycans (LAM, LM and PIM6) and lipoproteins, mycobacteria were delipidated by several extractions with 
CHCl3/CH3OH (1:1, v/v). Delipidated cells were then disrupted by sonication and further extracted by refluxing 
in 50% ethanol at 65 °C46. Ethanol/water extract was dried and used in subsequent experiments.
Construction of a M. tuberculosis H37RvΔRv1159 mutant. The Ts/sacB method was 
used to achieve allelic replacement at the pimE (Rv1159) locus of M. tuberculosis H37Rv (ATCC 
25618)61. pimE  and flanking regions were PCR-amplified using the pair of primers Rv1159.5 
(5′-ggcggcgggtgcgggttccgc-3′)/Rv1159.6 (5′-ccaagttgacggcggccaccg-3′) and a disrupted allele was obtained 
by replacing 964 bp of the coding sequence of this gene bracketed between two SmaI sites by the Kan 
cassette from pUC4K (Amersham Pharmacia Biotech). Mutant clones were confirmed by PCR using 
the set of primers Rv1159.1 (5′-CCCGGCCCATATGTGCCGCACCCTGATCGAC-3′) and Rv1159.2 
(5′-CCCAAGCTTATTGGCCATGCGCCGCGGCC-3′). Allelic replacement at the pimE locus of eight candidate 
mutant clones was confirmed by PCR (Fig. S3A). Negative ion mode MALDI-TOF-MS analyses of the PIM con-
tent of one of the mutants, performed as previously described62, revealed a complete absence of PIM6 acyl-forms 
with a concomitant increase in PIM4 acyl-forms (Fig. S3B), indicating that the disruption of pimE had the same 
effects on polar PIM synthesis in M. tuberculosis as the inactivation of the orthologous gene (MSMEG_5149) in 
M. smegmatis30.
Monosaccharide analysis. Mannoconjugates were submitted to strong acid hydrolysis with 2 M trifluoro-
acetic acid at 110 °C for 2 h and then dried under speed-vacuum. The resulting monosaccharides were derivatized 
for 90 min at 55 °C using a solution of 0.2 M 1-aminopyrene-3,6,8-trisulfonate (APTS) in 15% acetic acid and 1 M 
sodium cyanoborohydride solution dissolved in tetrahydrofuran. The APTS-labelled monosaccharides were sus-
pended in water and subjected to analysis by capillary electrophoresis monitored by laser-induced fluorescence, 
as previously described63.
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Binding of Dectin-2-Fc. Mannoconjugates (1 μg/well in isopropanol) or mycobacteria (heat-inactivated, 
106/well in isopropanol) were coated on 96-wells Maxisorp plates (Nunc). Dectin-2-Fc, a soluble form of the 
human Dectin-2 receptor, was constructed by fusing the C-terminal extracellular domain of human Dectin-2 
(aa 42–209) to the C-terminus of an engineered human IgG1 Fc domain. A soluble form of the murine Dectin-1 
receptor fused to the same human IgG1-Fc domain was used as a non-relevant protein control (IgG1 Fc con-
trol). hDectin-2-Fc and IgG1-Fc control proteins were expressed in CHO cells and purified by G protein affin-
ity chromatography. Human IgG1-Fc control or Dectin-2-Fc fusion proteins (1 μg/ml in PBS, 1 mM CaCl2, 1% 
BSA) were pre-incubated or not with 20 mM EDTA or 40 mM mannose (Sigma) and were allowed to react with 
mannoconjugates or bacterial cells for 2 h at RT (in 50 μl). Wells were washed once with PBS and the bound Fc 
fusion proteins were detected using biotin-conjugated anti-human IgG Fcγ specific antibodies (eBioscience) and 
avidin-horseradish peroxidase (eBioscience).
Dectin-2 and TLR2 reporter cell lines experiments. The HEK-BlueTM mDectin-2 and HEK-BlueTM 
hTLR2 (InvivoGen), derivatives of HEK293 cells that stably express the murine Dectin-2 or human TLR2 genes 
respectively, along with a NF-κB-inducible reporter system (secreted alkaline phosphatase) were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) containing 10% Fetal Bovine Serum (FBS, Gibco) 
4.5 g/l glucose, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin (Sigma) and 100 μg/ml zeo-
cin, 200 μg/ml hygromycin, 10 μg/ml blasticidin, 1 μg/ml puromycin and 50 μg/ml mofetil (all from InvivoGen). 
Mannoconjugates (1 μg/well in isopropanol, except in Figs 4B,D, 5B, 6B and S2C, from 300 ng to 10 ng/well in 
isopropanol, in Fig. S2D from 20 to 0.2 ng/well) or bacterial cells lysate (1 µg/well in isopropanol) were added to 
96-well plates, followed by evaporation of the solvents as previously described. Reporter cells (5 × 104/well) were 
stimulated for 24 h, after which alkaline phosphatase activity was measured by mixing 20 μl of the culture super-
natant and 180 μl of Quanti-BlueTM (InvivoGen), and reading O.D. at 630 nm.
Generation and activation of murine bone marrow-derived dendritic cells. All methods were 
carried out in accordance with the Centre National de la Recherche Scientifique guidelines and regulations for 
housing and care of laboratory animals. All experimental protocols were approved by the Structure chargée du 
bien-être animal (no. 2015.Ni.15). Bone marrow cells were flushed from the tibias and femurs of C57BL/6 mice 
(Janvier) with 5 ml of cold DMEM. The cell suspension was cultured at a density of 106 cells/ml in Iscove’s mod-
ified Dulbecco’s medium (IMDM, Lonza) supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml strepto-
mycin, 50 μM 2-mercaptoethanol and 10% J558 cell conditioned medium (as a source of GM-CSF). On day 3, 
fresh medium containing GM-CSF was added and on day 6 one half of the medium was renewed. BMDCs were 
harvested and used on day 8. They were distributed in 96-well plates at 2 × 105 cells/well to wells previously coated 
with mannoconjugates (0.1 µg/well) or bacterial cells lysate (1 µg/well) as described above. After 18 h, TNF-α 
was assayed in the culture supernatant using a commercially available kit (eBioscience). To investigate Dectin-2 
dependence, BMDCs were pre-incubated for 30 min at 37 °C with 5 μg/ml of anti-mDectin-2 antibody (clone 
11E4, Life Technology) or isotype control (rIgG2a, eBiosciences).
Statistical analysis. Data are expressed as mean ± SEM and were analyzed using Two-way analysis of vari-
ance followed by Tukey test to determine significant differences between samples.
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